GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anterogen Co Ltd (XKRX:065660) » Definitions » EBITDA Margin %

Anterogen Co (XKRX:065660) EBITDA Margin % : -10.64% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Anterogen Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anterogen Co's EBITDA for the three months ended in Mar. 2024 was ₩-163 Mil. Anterogen Co's Revenue for the three months ended in Mar. 2024 was ₩1,533 Mil. Therefore, Anterogen Co's EBITDA margin for the quarter that ended in Mar. 2024 was -10.64%.


Anterogen Co EBITDA Margin % Historical Data

The historical data trend for Anterogen Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anterogen Co EBITDA Margin % Chart

Anterogen Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.89 -82.96 18.65 -66.64 -7.45

Anterogen Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.56 -69.07 -34.40 25.52 -10.64

Competitive Comparison of Anterogen Co's EBITDA Margin %

For the Biotechnology subindustry, Anterogen Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anterogen Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anterogen Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Anterogen Co's EBITDA Margin % falls into.



Anterogen Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Anterogen Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-484.445/6500.25
=-7.45 %

Anterogen Co's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-163.048/1532.697
=-10.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anterogen Co  (XKRX:065660) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Anterogen Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Anterogen Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anterogen Co (XKRX:065660) Business Description

Traded in Other Exchanges
N/A
Address
Namsung Plaza, Gasan-dong, 405, 130, Digital-ro, Geumcheon-gu, Seoul, KOR, 08589
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Anterogen Co (XKRX:065660) Headlines

No Headlines